The world’s leading health organizations supporting celiac disease awareness and education (Celiac Disease Foundation, American Celiac Disease Alliance, Celiac Sprue Association, Gluten Intolerance Group and the National Foundation for Celiac Awareness) applaud the efforts of Alvine Pharmaceuticals and AbbVie in addressing the significant unmet medical need for therapeutic treatment of celiac disease. ALV003 is an investigational oral therapy composed of two recombinant, gluten specific enzymes (a cysteine protease (EP-B2) and a prolyl endopeptidase (PEP)), that degrade gluten in-vitro and in human clinical testing, and may reduce the symptoms and intestinal injury associated with celiac disease in patients attempting to adhere to a gluten-free diet.
5/14/2013
Progress Toward Oral Therapy for Celiac Disease
Recent Posts
- Attention Researchers: CDMRP Funding Opportunities Now Available
- Meet Jennifer, Advocate and CDF Assistant Director of Community Engagement
- Addressing Health Equity and Clinical Disparities – Marilyn’s Message February 2024
- Underrepresented Populations in Celiac Disease, A New Grant, and Collaborations to Improve Health Equity in Celiac Disease
Search the archive
Categories
- Advocacy News
- Celiac Disease in the News
- Clinical Trials
- Eat! Gluten-Free
- Featured
- Foundation Press
- iCureCeliac
- Marilyn’s Message
- Monthly eNewsletter
- Patient Profile Advocacy Series
- Research News
- Research Press
- Trending Topics
Marilyn's Message
2/29/2024
Read moreAddressing Health Equity and Clinical Disparities – Marilyn’s Message February 2024
As we continue our journey toward advancing awareness and understanding of celiac disease, it is crucial that we reflect on health equity and the persistent clinical disparities within our community—so that together we can confront these factors and dismantle barriers hindering access to care and support. Health equity represents the...